FLAG-Ida Achieves 57 Percent Remission in Relapsed Acute Myeloid Leukemia

Navigating the Salvage Landscape in Relapsed AML

Managing relapsed or refractory acute myeloid leukemia remains a significant clinical challenge, as patients treated with standard salvage chemotherapy often face a five year overall survival rate below 50 percent [1, 2, 3]. While the therapeutic landscape now includes second-generation FMS-like tyrosine kinase 3 (FLT3) inhibitors and B-cell lymphoma 2 (BCL-2) antagonists, these agents are often utilized as bridges to definitive therapy or for specific molecular cohorts [4, 5, 6]. In the ADMIRAL trial, for instance, gilteritinib demonstrated a median overall survival of 9.3 months compared to 5.6 months for salvage chemotherapy (hazard ratio, 0.665; 95% CI, 0.518 to 0.853) [6]. Although allogeneic hematopoietic cell transplantation is the primary curative path, the necessity of achieving complete remission prior to transplant is increasingly questioned; the ASAP trial found no survival advantage for intensive salvage chemotherapy over immediate transplant with sequential conditioning [2, 7]. High-dose, multi-agent regimens continue to be scrutinized for their toxicity profiles, particularly as newer liposomal formulations have shown a reduced 60 day mortality of 16.1 percent versus 24.1 percent in poor-risk patients [8, 9]. A new large-scale multicenter study now provides critical real-world data on a long-standing intensive regimen, offering a benchmark for modern clinical practice.

Real-World Efficacy in a Large Multicenter Cohort

A comprehensive analysis of a large multicenter real-world cohort has established a clear performance baseline for intensive salvage therapy, comprising 1,079 adults with relapsed or refractory acute myeloid leukemia. This extensive study utilized data from 112 PETHEMA institutions, spanning a 26-year period from 1998 to 2024. The patient population had a median age of 52 years, representing a clinically relevant demographic of fit adults often considered for intensive salvage therapy. Within this cohort, the clinical presentation was divided between 36.9 percent of patients with primary refractory disease (leukemia that failed to respond to initial induction therapy) and 63.1 percent who were experiencing their first relapse episode. The primary efficacy endpoint focused on the ability of the FLAG-Ida regimen (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) to induce remission. The study reported a complete remission composite rate of 56.8 percent, a critical metric for clinicians determining the likelihood of clearing a patient's marrow. When disaggregated, the data showed that complete remission was achieved in 51.0 percent of patients, while 4.0 percent experienced complete remission with incomplete recovery (a state where marrow blasts are below 5 percent but peripheral blood counts have not fully normalized). Additionally, a morphological-free-state was achieved in 1.8 percent of patients, indicating the disappearance of visible leukemic blasts despite the lack of full hematologic recovery.

Bridging to Transplant and Long-Term Survival

For clinicians managing relapsed or refractory acute myeloid leukemia, the primary utility of intensive salvage therapy is its capacity to serve as a bridge to definitive treatment. The study demonstrated that the FLAG-Ida regimen effectively facilitated this transition, as 35.2 percent of the total cohort proceeded to allogeneic transplantation without morphological disease (the presence of leukemic blasts visible under a microscope). This achievement of a morphological-free state is a critical clinical milestone, as it allows patients to enter the transplant process with a lower disease burden, which is historically associated with better post-transplant outcomes. Among the subset of patients who achieved a clinical response to the therapy, the rate of transition was even higher, with 62 percent of responders proceeding to allogeneic transplantation. The long-term durability of these outcomes was evaluated over a median follow-up period of 50.9 months, providing a comprehensive view of patient trajectories. For the entire cohort of 1,079 patients, the median overall survival was 10.2 months. While the prognosis for relapsed disease remains challenging, the intensive salvage approach resulted in a 5-year overall survival rate of 21.6 percent. These data provide practicing physicians with a clear benchmark for the expected survival benefit of FLAG-Ida in fit adults, highlighting its role in securing long-term survival for approximately one-fifth of this high-risk population through successful cytoreduction and subsequent stem cell transplantation.

Predictors of Survival and Molecular Risk Factors

The researchers identified several clinical variables that independently predicted better outcomes for patients undergoing FLAG-Ida salvage therapy, offering clinicians a more nuanced way to select candidates for intensive treatment. Notably, prior allogeneic transplantation independently predicted improved overall survival with a hazard ratio of 0.54 (p < 0.001), suggesting that patients who had previously undergone a stem cell transplant maintained a survival advantage during salvage. Additionally, the duration of the first remission proved to be a significant prognostic indicator; a relapse-free interval of 1 year or longer independently predicted improved overall survival with a hazard ratio of 0.75 (p = 0.024). These findings suggest that patients with more indolent disease biology or those who have already demonstrated the ability to tolerate intensive therapy may derive the greatest benefit from this regimen. Conversely, specific molecular and cytogenetic markers were associated with significantly poorer prognosis. The presence of modified high-risk cytogenetics, including t(8; 21), conferred inferior overall survival with a hazard ratio of 3.58 (p < 0.001). This high hazard ratio (a statistical measure indicating that these patients were more than three times as likely to die during the follow-up period compared to those without these markers) underscores the difficulty of treating this subgroup with standard intensive salvage. Furthermore, the presence of the FLT3-ITD mutation at primary diagnosis conferred inferior overall survival with a hazard ratio of 1.61 (p < 0.001). This internal tandem duplication in the FLT3 gene, a common driver of leukemic proliferation, remains a negative prognostic factor even when intensive salvage regimens like FLAG-Ida are employed. Patient age also played a decisive role in survival outcomes, as an age of 60 years or older conferred inferior overall survival with a hazard ratio of 1.43 (p < 0.001).

Validating the SALFLAGE Prognostic Score

To assist clinicians in synthesizing complex prognostic variables, the researchers performed a validation of the SALFLAGE score, a clinical tool designed to predict outcomes specifically for patients undergoing salvage therapy for relapsed or refractory acute myeloid leukemia. In this large multicenter cohort, the score demonstrated moderate discrimination with a C-index of 0.67. This concordance index (a statistical measure where 0.5 indicates no predictive power and 1.0 indicates perfect accuracy) suggests that the SALFLAGE model provides a reliable framework for estimating patient survival in a real-world clinical setting. The utility of the SALFLAGE score in clinical counseling is further evidenced by its ability to stratify patients into three distinct risk groups with significantly different long-term outcomes. The study found that the 5-year survival rates across SALFLAGE risk categories were 38.4 percent, 27.2 percent, and 12.7 percent (p < 0.001). By applying this scoring system, physicians can more accurately identify which patients are likely to achieve durable remissions and which may require alternative therapeutic strategies or early palliative considerations. This validation confirms that the SALFLAGE score remains a relevant prognostic instrument for managing fit adults treated with intensive salvage regimens like FLAG-Ida, raising the prospect that future diagnostic tools could better match patients to targeted interventions based on their neurobiological and clinical profile.

Evolution of Care and Safety Over Three Decades

The researchers evaluated how the efficacy and safety of the FLAG-Ida regimen changed over the 26-year study period by comparing outcomes across three distinct chronological eras: 1998 to 2005, 2006 to 2016, and 2017 to 2024. This longitudinal analysis reflects the evolution of supportive care and clinical management in the treatment of relapsed or refractory acute myeloid leukemia. A key finding was the significant reduction in early treatment-related complications in the most recent cohort. The 30-day mortality rates across the three periods were 6.9 percent, 9.3 percent, and 5.0 percent, respectively (p = 0.030). This decline in early mortality during the 2017 to 2024 period suggests that improvements in infection control, transfusion support, and patient selection have enhanced the safety profile of this intensive salvage protocol. While early safety improved significantly, the researchers also observed a steady, though not statistically significant, upward trend in long-term efficacy. The median overall survival across the three periods was 7.8 months, 9.4 months, and 11.1 months, respectively (p = 0.16). Although the p-value indicates that this increase did not reach the threshold for statistical significance, the absolute gain of 3.3 months between the earliest and latest eras may reflect the cumulative impact of better post-remission care and more effective bridging to allogeneic transplantation. These findings reinforce the role of FLAG-Ida as a stable reference regimen that continues to provide a viable pathway to transplant for fit patients in the modern era of hematology.

References

1. Lin W, Chao C, Lin C, Hsu Y, Hsiao S, Weng T. Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials.. Molecular and clinical oncology. 2024. doi:10.3892/mco.2024.2791

2. Stelljes M, Middeke JM, Bug G, et al. Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.. Blood. 2025. doi:10.1182/blood.2025028730

3. Mix L, Schroeder JC, Ahmad O, et al. Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch). Blood. 2025. doi:10.1182/blood-2025-8253

4. Gupta SV, Jose N, Tafuto B. The Impact of Gilteritinib on Overall Survival of Adult Patients with FLT3 Positive Acute Myeloid Leukemia: A Systematic Review.. Principles and practice of clinical research (2015). 2024. doi:10.21801/ppcrj.2024.102.7

5. Mohebbi A, Shahriyary F, Farrokhi V, Bandar B, Saki N. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.. Leukemia research. 2024. doi:10.1016/j.leukres.2024.107505

6. Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. Blood. 2022. doi:10.1182/blood.2021011583

7. Ganguly S, Cortes J, Krämer A, et al. Clinical Outcomes in Patients With FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.. Biology of Blood and Marrow Transplantation. 2020. doi:10.1016/j.bbmt.2020.09.036

8. Jaramillo S, Cornet LL, Kratzmann M, et al. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.. Trials. 2023. doi:10.1186/s13063-023-07421-x

9. Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.. Cancer. 2015. doi:10.1002/cncr.28974